Replication-defective adenovirus vectors were generated inoculated on day 0 with 10 5 II-45 cells into the pleural in which the gene of interest (lacZ, luciferase or HSV-tk) is cavity, received 7 × 10 9 infectious particles of IG.Ad. driven by the adenovirus major late promoter (MLP) or CMV.TK on day 1, day 2, day 4 or day 8. One day after the human cytomegalovirus immediate-early gene virus administration, 25 mg/kg GCV or PBS (controls) was promoter/enhancer (CMV). In vitro experiments with rat (IIinjected i.p. (intraperitoneally) twice daily. On day 15, all 45) and human (MERO 25) mesothelioma cell lines animals were killed. Significant tumor regression, equivalrevealed that the CMV promoter was stronger than the ent to 5 log cell kill, occurred in the treated rats suggesting MLP promoter regarding levels of expression of the luciferan impressive bystander effect. In a survival study, animals ase reporter gene and ganciclovir (GCV) killing efficiency were treated 9 days after inoculation of 10 5 tumor cells with after tk gene transfer. Following administration of IG.Ad.CMV.TK and a 14 days course of GCV. This treat-IG.Ad.CMV.lacZ recombinant adenovirus (Introgene, IG) ment prolonged symptom-free survival time from 19 days into the pleural cavity of Fischer rats with established in the controls to 33 days in the treated group. These mesothelioma, a widespread distribution of infectious virus responses can be best explained by assuming continued particles through the thorax contents was demonstrated.tk expression in or around the tumor tissue during GCV However, a relatively small proportion of tumor cells were treatment. Our results confirm and extend earlier findings transduced. Nevertheless, a strong tumor growth inhibition with the same model and demonstrate the potential of the was observed following treatment with IG.Ad.CMV.TK herpes simplex virus thymidine kinase suicide gene recombinant adenovirus and GCV. Separate groups of rats therapy as a local treatment for malignant mesothelioma.
This study demonstrates the therapeutic efficiency and feasibility of the TK/GCV approach in experimental brain tumors and leptomeningeal metastases. It also demonstrates that the promoter driving the transgene in an adenoviral vector influences toxicity and efficiency of treatment.
Cytokine gene therapy was studied in established L42 tumour responses. These were due to local release of cytotumours in syngeneic rats. L42 is a transplantable nonkines, not to systemic effects. Growth retardation also immunogenic non-small cell lung cancer (NSCLC). Genes occurred in contralateral tumours which were not injected. coding for human interleukin-1␣ and for rat interleukin-3When rats carrying established tumours were vaccinated were transferred by injecting producer cells of recombinant with lysates of tumours collected during treatment with adenovirus vectors into the tumour in attempts to achieve 'cracked' producer cells, significant tumour growth retarhigh concentrations of the cytokines inside the tumor withdation was obtained. We speculate that both cytokines, if out systemic toxicity. Limited tumour growth delay was produced at sufficiently high concentrations in tumours, obtained with viable producer cells. For logistic reasons induce inflammation which in turn initiates an immune stocks of pooled frozen producer cells allowed intensive response against tumours growing at a distant site. These treatment of groups of tumour bearing rats. The cells were findings seem to justify further exploration of IL-1 and IL-3 lysed by thawing before administration. Ten daily injections gene transfer for the treatment of cancers. of such 'cracked' producer cells induced reproducible
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.